Literature DB >> 11474576

Increased cytokine-induced cytotoxicity of pancreatic islet cells from transgenic mice expressing the Src-like tyrosine kinase GTK.

C Annerén1, M Welsh.   

Abstract

BACKGROUND: The loss of beta cells in type 1 diabetes may involve protein kinases because they control cell growth, differentiation, and survival. Previous studies have revealed that GTK, a Src-like protein tyrosine kinase expressed in beta cells (also named Bsk/Iyk), regulates multiple responses including growth and survival of rat insulinoma cells (RINm5F) and differentiation of neuronal PC12 cells. In the present study, we have generated a transgenic mouse expressing a kinase active GTK mutant (GTK-Y504F) under the control of the rat insulin I promoter to establish a role of GTK in beta cells.
MATERIALS AND METHODS: Control and GTK-transgenic CBA mice were used for determination of in vivo glucose tolerance and the relative insulin-positive area. Isolated islets from both groups were cultured in the absence and presence of cytokines and insulin secretion, viability and protein expression were assessed.
RESULTS: The beta-cell mass of GTK-transgenic mice was increased as a consequence of a larger pancreas and an increased relative beta-cell area. Islets isolated from the transgenic animals exhibited an enhanced glucose-induced insulin release and reduced viability in response to cytokines that could not be explained by higher levels of nitric oxide (NO) compared with control islets. Extracellular signal-regulated kinase (ERK) 1/2, p38 mitogen-activated protein kinase (MAPK), c-Jun NH2-terminal kinase (JNK), and Akt were all activated by cytokines, but GTK-transgenic islets contained higher basal levels of phosphorylated ERK1/2 and lower basal levels of phosphorylated p38 compared with the control islets. The total amount of activated MAPKs was, however, higher in the cytokine-stimulated transgenic islets compared with the control islets due to increased levels of phospho-ERK1/2. Moreover, the proline-rich tyrosine kinase (PYK) 2 (also named RAFTK/CAK beta/CADTK) levels were elevated in response to a 24-hr exposure to cytokines in control islets but not in the GTK-transgenic islets.
CONCLUSIONS: These results suggest that although GTK increases the beta-cell mass, it also enhances islet cell death in response to cytokines and may thus be involved in the beta-cell damage in type 1 diabetes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11474576      PMCID: PMC1950041     

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  7 in total

1.  Assessment of Relationship between Fyn-related Kinase Gene Polymorphisms and Overweight/Obesity in Korean Population.

Authors:  Mi Young Jung; Bum Shik Kim; Youn Jung Kim; In Song Koh; Joo-Ho Chung
Journal:  Korean J Physiol Pharmacol       Date:  2008-04-30       Impact factor: 2.016

Review 2.  RAKing in AKT: a tumor suppressor function for the intracellular tyrosine kinase FRK.

Authors:  Patrick M Brauer; Angela L Tyner
Journal:  Cell Cycle       Date:  2009-09-29       Impact factor: 4.534

3.  The tyrosine kinase FRK/RAK participates in cytokine-induced islet cell cytotoxicity.

Authors:  Michael Welsh; Charlotte Welsh; Maria Ekman; Johan Dixelius; Robert Hägerkvist; Cecilia Annerén; Björn Akerblom; Siavosh Mahboobi; Subhashini Chandrasekharan; Edison T Liu
Journal:  Biochem J       Date:  2004-08-15       Impact factor: 3.857

4.  Individuals Diagnosed with Binge-Eating Disorder Have DNA Hypomethylated Sites in Genes of the Metabolic System: A Pilot Study.

Authors:  Mariana Lizbeth Rodríguez-López; José Jaime Martínez-Magaña; David Ruiz-Ramos; Ana Rosa García; Laura Gonzalez; Carlos Alfonso Tovilla-Zarate; Emmanuel Sarmiento; Isela Esther Juárez-Rojop; Humberto Nicolini; Thelma Beatriz Gonzalez-Castro; Alma Delia Genis-Mendoza
Journal:  Nutrients       Date:  2021-04-22       Impact factor: 5.717

5.  Integration of single-cell datasets reveals novel transcriptomic signatures of β-cells in human type 2 diabetes.

Authors:  Emanuele Bosi; Lorella Marselli; Carmela De Luca; Mara Suleiman; Marta Tesi; Mark Ibberson; Decio L Eizirik; Miriam Cnop; Piero Marchetti
Journal:  NAR Genom Bioinform       Date:  2020-11-20

Review 6.  Emerging Kinase Therapeutic Targets in Pancreatic Ductal Adenocarcinoma and Pancreatic Cancer Desmoplasia.

Authors:  Justin F Creeden; Khaled Alganem; Ali S Imami; Nicholas D Henkel; F Charles Brunicardi; Shi-He Liu; Rammohan Shukla; Tushar Tomar; Faris Naji; Robert E McCullumsmith
Journal:  Int J Mol Sci       Date:  2020-11-21       Impact factor: 5.923

7.  FRK inhibits breast cancer cell migration and invasion by suppressing epithelial-mesenchymal transition.

Authors:  Yetunde Ogunbolude; Chenlu Dai; Edward T Bagu; Raghuveera Kumar Goel; Sayem Miah; Joshua MacAusland-Berg; Chi Ying Ng; Rajni Chibbar; Scott Napper; Leda Raptis; Frederick Vizeacoumar; Franco Vizeacoumar; Keith Bonham; Kiven Erique Lukong
Journal:  Oncotarget       Date:  2017-12-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.